Cited by 1,709Antibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacySynthesis of β-Lactam Compounds

The DOI matches its Crossref record; 462 of the 464 references it cites were found in a registry or an index.

Three Decades of β-Lactamase Inhibitors

Open access

Drawz, Sarah M., Bonomo, Robert A.·2010·Clinical Microbiology Reviews

Open this paper in CoChat — free account

Abstract

Since the introduction of penicillin, beta-lactam antibiotics have been the antimicrobial agents of choice. Unfortunately, the efficacy of these life-saving antibiotics is significantly threatened by bacterial beta-lactamases. beta-Lactamases are now responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome beta-lactamase-mediated resistance, beta-lactamase inhibitors (clavulanate, sulbactam, and tazobactam) were introduced into clinical practice. These inhibitors greatly enhance the efficacy of their partner beta-lactams (amoxicillin, ampicillin, piperacillin, and ticarcillin) in the treatment of serious Enterobacteriaceae and penicillin-resistant staphylococcal infections. However, selective pressure from excess antibiotic use accelerated the emergence of resistance to beta-lactam-beta-lactamase inhibitor combinations. Furthermore, the prevalence of clinically relevant beta-lactamases from other classes that are resistant to inhibition is rapidly increasing. There is an urgent need for effective inhibitors that can restore the activity of beta-lactams. Here, we review the catalytic mechanisms of each beta-lactamase class. We then discuss approaches for circumventing beta-lactamase-mediated resistance, including properties and characteristics of mechanism-based inactivators. We next highlight the mechanisms of action and salient clinical and microbiological features of beta-lactamase inhibitors. We also emphasize their therapeutic applications. We close by focusing on novel compounds and the chemical features of these agents that may contribute to a "second generation" of inhibitors. The goal for the next 3 decades will be to design inhibitors that will be effective for more than a single class of beta-lactamases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/cmr.00037-09

Cites

462 of 462 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,495
Self-citation
Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,646
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,609
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,485
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,328
AmpC β-Lactamases
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,277
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,068
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,619
Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux
Nikaido, H. (1994) · Science · doi:10.1126/science.8153625 · Cited by 1,542

Show all 464 references

Research works printed but not linked: 14

Danel, F., M. G. Page, and D. M. Livermore. 2007. Class D β-lactamases, p. 163-194. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Dubus, A., P. Ledent, J. Lamotte-Brasseur, and J. M. Frere. 1996. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases. Proteins25:473-485.
Foulds, G., W. E. Barth, J. R. Bianchine, A. R. English, D. Girard, S. L. Hayes, M. O'Brien, and P. Somani. 1980. Pharmacokinetics of CP-45.899 and pro-drug CP-47.904 in animals and humans, p. 353-356. In J. D. Nelson and C. Grassi (ed.), Current chemotherapy and infectious disease. American Society for Microbiology, Washington DC.
Galleni, M., and J. M. Frere. 2007. Kinetics of β-lactamases and pencillin-binding proteins, p. 195-213. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
F1-310. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
F1-333a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Livermore, D. M., M. Akova, P. J. Wu, and Y. J. Yang. 1989. Clavulanate and β-lactamase induction. J. Antimicrob. Chemother.24(Suppl. B):23-33.
A1-006. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. 2009
Meroueh, S., J. Cha, and S. Mobashery. 2007. Inhibition of class A β-lactamases, p. 101-114. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washingtion, DC.
Page, M. G. 2007. Resistance mediated by penicllin-binding proteins, p. 81-99. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for Inhibition. ASM Press, Washington, DC.
F1-311. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
F1-0882. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
Slocombe, B., A. S. Beale, R. J. Boon, K. E. Griffin, P. J. Masters, R. Sutherland, and A. R. White. 1984. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid, p. 29-49. InProgress and perspectives on β-lactamase inhibition: a review of Augmentin. Custom Communications: Postgraduate Medicine, New York, NY.

Sorted by citations

Items 201–300 of 1,001

Antimicrobial resistance challenged with metal-based antimicrobial macromolecules
Abd‐El‐Aziz, A. S., Agatemor, C., & Etkin, N. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.002 · Cited by 93
TEM-1 -lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii
Krizova, L., Poirel, L., Nordmann, P., & Nemec, A. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt275 · Cited by 93
Bile salt hydrolases: Structure and function, substrate preference, and inhibitor development
Dong, Z., & Lee, B. H. (2018) · Protein Science · doi:10.1002/pro.3484 · Cited by 92
Indirect resistance to several classes of antibiotics in cocultures with resistant bacteria expressing antibiotic-modifying or -degrading enzymes
Nicoloff, H., & Andersson, D. I. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv312 · Cited by 94
Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
Ofer-Friedman, H., Shefler, C., Sharma, S., Tirosh, A., Tal-Jasper, R., Kandipalli, D., Sharma, S., Bathina, P., Kaplansky, T., Maskit, M., et al. (2015) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2015.101 · Cited by 91
Cyclic Boronates Inhibit All Classes of β-Lactamase
Cahill, S. T., Cain, R. M., Wang, D. Y., Lohans, C. T., Wareham, D. W., Oswin, H. P., Mohammed, J., SPENCER, J. M., Fishwick, C. W. G., McDonough, M. A., et al. (2017) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 91
Pharmacokinetic evaluation of piperacillin-tazobactam
Hayashi, Y., Roberts, J. A., Paterson, D. L., & Lipman, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.506187 · Cited by 91
A comprehensive review on pharmacology of efflux pumps and their inhibitors in antibiotic resistance
Thakur, V., Uniyal, A., & Tiwari, V. K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174151 · Cited by 96
Synthesis and Antibacterial Activity of Ionic Liquids and Organic Salts Based on Penicillin G and Amoxicillin hydrolysate Derivatives against Resistant Bacteria
Ferraz, R., Silva, D., Dias, A. R., Dias, V., Santos, M. M., Pinheiro, L., Prudêncio, C., Noronha, J. P., Petrovski, Ž., & Branco, L. C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030221 · Cited by 89
Kinugasa reaction: an ‘ugly duckling’ of β-lactam chemistry
Stecko, S., Furman, B., & Chmielewski, M. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.06.024 · Cited by 87
Molecular Basis of Class A β-Lactamase Inhibition by Relebactam
Tooke, C. L., Hinchliffe, P., Lang, P. A., Mulholland, A. J., Brem, J., Schofield, C. J., & SPENCER, J. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00564-19 · Cited by 87
Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
Krishnan, N. P., Nguyen, N. Q., Papp‐Wallace, K. M., Bonomo, R. A., & van den Akker, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136813 · Cited by 87
Self-citation
The secondary resistome of multidrug-resistant Klebsiella pneumoniae
Jana, B., Cain, A. K., Doerrler, W. T., Boinett, C. J., Fookes, M. C., Parkhill, J., & Guardabassi, L. (2017) · Scientific Reports · doi:10.1038/srep42483 · Cited by 87
Metal–carbenicillin framework-based nanoantibiotics with enhanced penetration and highly efficient inhibition of MRSA
Duan, F., Feng, X., Jin, Y. J., Liu, D., Yang, X., Zhou, G., Liu, D., Li, Z., Liang, X., & Zhang, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.024 · Cited by 86
Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics
Sun, Z., Hu, L., Sankaran, B., Prasad, B. V. V., & Palzkill, T. G. (2018) · Nature Communications · doi:10.1038/s41467-018-06839-1 · Cited by 87
Characterization of BKC-1 Class A Carbapenemase from Klebsiella pneumoniae Clinical Isolates in Brazil
Nicoletti, A. G., Marcondes, M. F., Martins, W. M. B. S., de Almeida, L. G. P., Nicolas, M. F., de Vasconcelos, A. T. R., Oliveira, V., & Gales, A. C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00158-15 · Cited by 85
The future of antibiotics begins with discovering new combinations
Zhu, M., Tse, M. W., Weller, J., Chen, J., & Blainey, P. C. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14649 · Cited by 88
Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
Rholl, D. A., Papp‐Wallace, K. M., Tomaras, A. P., Vasil, M. L., Bonomo, R. A., & Schweizer, H. P. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00139 · Cited by 84
Self-citation
Active-Site Conformational Fluctuations Promote the Enzymatic Activity of NDM-1
Zhang, H., Ma, G., Zhu, Y., Zeng, L., Ahmad, A., Wang, C., Pang, B., Fang, H., Zhao, L., & Hao, Q. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01579-18 · Cited by 83
Highly parallel lab evolution reveals that epistasis can curb the evolution of antibiotic resistance
Lukačišinová, M., Fernando, B., & Bollenbach, T. (2020) · Nature Communications · doi:10.1038/s41467-020-16932-z · Cited by 80
Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates
Lee, N., Lee, C., Li, C., Li, M.-C., Chen, P., Chang, C., & Ko, W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01477-15 · Cited by 83
New trends in the use of aminoglycosides
Fosso, M. Y., Li, Y., & Garneau‐Tsodikova, S. (2014) · MedChemComm · doi:10.1039/c4md00163j · Cited by 82
Zinc ion-induced conformational changes in new Delphi metallo-β-lactamase 1 probed by molecular dynamics simulations and umbrella sampling
Chen, J., Wang, J., & Zhu, W. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp08105c · Cited by 82
β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
Alfei, S., & Schito, A. M. (2022) · Pharmaceuticals · doi:10.3390/ph15040476 · Cited by 82
Structure of New Delhi metallo-β-lactamase 1 (NDM-1)
Green, V. L., Verma, A. K., Owens, R. J., Phillips, S. E. V., & Carr, S. B. (2011) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309111029654 · Cited by 82
Determining a clinical framework for use of cefepime and -lactam/ -lactamase inhibitors in the treatment of infections caused by extended-spectrum- -lactamase-producing Enterobacteriaceae
Nguyen, H. M., Shier, K. L., & Graber, C. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt450 · Cited by 81
Tackling the Antibiotic Resistance Caused by Class A β-Lactamases through the Use of β-Lactamase Inhibitory Protein
Eiamphungporn, W., Schaduangrat, N., Malik, A. A., & Nantasenamat, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082222 · Cited by 81
Carbapenemase-producing bacteria in food-producing animals, wildlife and environment: A challenge for human health
Bonardi, S., & Pitino, R. (2019) · Italian Journal of Food Safety · doi:10.4081/ijfs.2019.7956 · Cited by 81
Metallo-β-Lactamase Inhibitors Inspired on Snapshots from the Catalytic Mechanism
Palacios, A. R., Rossi, M.-A., Mahler, G., & Vila, A. J. (2020) · Biomolecules · doi:10.3390/biom10060854 · Cited by 82
Avibactam and Inhibitor-Resistant SHV β-Lactamases
Winkler, M., Papp‐Wallace, K. M., Taracila, M. A., & Bonomo, R. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04405-14 · Cited by 81
Self-citation
Global spread of New Delhi mettallo-beta-lactamase-1(NDM-1).
Fallah, F., Taherpour, A., Hakemi-Vala, M., & Hashemi, A. (2011) · Archives of Clinical Infectious Diseases · Cited by 79
Insight into the Effect of Inhibitor Resistant S130G Mutant on Physico-Chemical Properties of SHV Type Beta-Lactamase: A Molecular Dynamics Study
Baig, M. H., Sudhakar, D., Ponnusamy, K., Subbarao, N., Wadhawa, G., Lohani, M., Khan, M. K. A., & Khan, A. U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112456 · Cited by 79
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae
Sutaria, D. S., Moyá, B., Green, K. B., Kim, T., Tao, X., Jiao, Y., Louie, A., Drusano, G. L., & Bulitta, J. B. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00282-18 · Cited by 79
Alarming Antibiotic Resistance of Lactobacilli Isolated from Probiotic Preparations and Dietary Supplements
Anisimova, E., Gorokhova, I., Karimullina, G. N., & Рашидовна, Я. Д. (2022) · Antibiotics · doi:10.3390/antibiotics11111557 · Cited by 84
Combatting resistance: Understanding multi-drug resistant pathogens in intensive care units
Teng, J., İmani, S., Zhou, A., Zhao, Y., Du, L., Deng, S., Li, J., & Wang, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115564 · Cited by 79
Multiple Global Suppressors of Protein Stability Defects Facilitate the Evolution of Extended-Spectrum TEM β-Lactamases
Brown, N. G., Pennington, J. M., Huang, W., Ayvaz, T., & Palzkill, T. G. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.10.008 · Cited by 79
Antibiotic Potentiators Against Multidrug-Resistant Bacteria: Discovery, Development, and Clinical Relevance
Chawla, M., Verma, J., Gupta, R., & Das, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.887251 · Cited by 76
Real‐Time Monitoring of New Delhi Metallo‐β‐Lactamase Activity in Living Bacterial Cells by 1 H NMR Spectroscopy
Ma, J., McLeod, S. M., MacCormack, K., Sriram, S., Gao, N., Breeze, A. L., & Hu, J. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308636 · Cited by 78
Detection of Carbapenemase‐Producing Organisms with a Carbapenem‐Based Fluorogenic Probe
Mao, W., Xia, L., & Xie, H. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201612495 · Cited by 78
Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniae
Endimiani, A., Hujer, K. M., Hujer, A. M., Pulse, M., Weiss, W. J., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-10 · Cited by 77
Self-citation
Allosteric communication in class A β-lactamases occurs via cooperative coupling of loop dynamics
Galdadas, I., Qu, S., Oliveira, A. S. F., Olehnovics, E., Mack, A. R., Mojica, M. F., Agarwal, P. K., Tooke, C. L., Gervasio, F. L., SPENCER, J. M., et al. (2021) · eLife · doi:10.7554/elife.66567 · Cited by 77
Self-citation
Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo
Eidam, O., Romagnoli, C., Dalmasso, G., Barelier, S., Caselli, E., Bonnet, R., Shoichet, B. K., & Prati, F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208337109 · Cited by 77
Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics
Jacobson, O., Kiesewetter, D. O., & Chen, X. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00487 · Cited by 78
Biochemical Activity of Vaborbactam
Tsivkovski, R., & Lomovskaya, O. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01935-19 · Cited by 79
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design
Wu, Y., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00790 · Cited by 76
Detection of AmpC β Lactamases in Gram-negative Bacteria
Gupta, G., Tak, V., & Mathur, P. (2014) · Journal of Laboratory Physicians · doi:10.4103/0974-2727.129082 · Cited by 76
Designing Irreversible Inhibitors—Worth the Effort?
González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74
NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors
Li, G., Abboud, M. I., Brem, J., Someya, H., Lohans, C. T., Yang, S., SPENCER, J. M., Wareham, D. W., McDonough, M. A., & Schofield, C. J. (2016) · Chemical Science · doi:10.1039/c6sc04524c · Cited by 74
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam
Shapiro, A. B. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01612-17 · Cited by 74
Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli
Schechter, L. M., Creely, D., Garner, C. D., Shortridge, D., Nguyen, H. T., Chen, L., Hanson, B., Sodergren, E. J., Weinstock, G. M., Dunne, W. M., et al. (2018) · mBio · doi:10.1128/mbio.00583-18 · Cited by 74
Fluorogenic Probes/Inhibitors of β‐Lactamase and their Applications in Drug‐Resistant Bacteria
Ding, Y., Li, Z., Xu, C., Qin, W., Wu, Q., Wang, X., Cheng, X., Li, L., & Huang, W. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006635 · Cited by 74
Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments
Giovagnorio, F., VITO, A. D., Madeddu, G., Parisi, S. G., & Geremia, N. (2023) · Antibiotics · doi:10.3390/antibiotics12111621 · Cited by 79
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients
Alobaid, A. S., Wallis, S. C., Jarrett, P., Starr, T., Stuart, J., Lassig‐Smith, M., Ordoñez, J., Roberts, M. S., Roger, C., Udy, A. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01276-16 · Cited by 74
Prevalence of β‐lactamase‐producing bacteria in human periodontitis
Rams, T. E., Degener, J. E., & Winkelhoff, A. J. V. (2012) · Journal of Periodontal Research · doi:10.1111/jre.12031 · Cited by 73
Recent Advances in Strategies to Combat Bacterial Drug Resistance: Antimicrobial Materials and Drug Delivery Systems
Yao, J., Zou, P., Cui, Y., Quan, L., Gao, C., Li, Z., Gong, W., & Yang, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041188 · Cited by 77
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
Watkins, R., Papp‐Wallace, K. M., Drawz, S. M., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00392 · Cited by 72
Self-citation
Captopril analogues as metallo-β-lactamase inhibitors
Yusof, Y., Tan, D. T. C., Arjomandi, O. K., Schenk, G., & McGeary, R. P. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.007 · Cited by 72
Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators
Hart, K. M., Moeder, K. E., Ho, C. M. W., Zimmerman, M. I., Frederick, T. E., & Bowman, G. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178678 · Cited by 75
High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam
Periasamy, H., Joshi, P., Palwe, S. R., Shrivastava, R., Bhagwat, S., & Patel, M. V. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa021 · Cited by 71
Design, Synthesis, Crystal Structures, and Antimicrobial Activity of Sulfonamide Boronic Acids as β-Lactamase Inhibitors
Eidam, O., Romagnoli, C., Caselli, E., Babaoglu, K., Pohlhaus, D. T., Karpiak, J. D., Bonnet, R., Shoichet, B. K., & Prati, F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101015z · Cited by 71
Histone Deacetylase Inhibitors as a Tool to Up-Regulate New Fungal Biosynthetic Products: Isolation of EGM-556, a Cyclodepsipeptide, from Microascus sp.
Vervoort, H. C., Drašković, M., & Crews, P. (2010) · Organic Letters · doi:10.1021/ol1027199 · Cited by 71
New antibiotics from Nature’s chemical inventory
Wencewicz, T. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.014 · Cited by 70
New promising β-lactamase inhibitors for clinical use
Olsen, I. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2375-0 · Cited by 70
Auxiliary factors: a chink in the armor of MRSA resistance to β-lactam antibiotics
Roemer, T., Schneider, T., & Pinho, M. G. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.012 · Cited by 69
Spectroscopic and Mechanistic Studies of Heterodimetallic Forms of Metallo-β-lactamase NDM-1
Yang, H., Aitha, M., Marts, A. R., Hetrick, A., Bennett, B., Crowder, M. W., & Tierney, D. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja410376s · Cited by 70
Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1
Heinz, E., Ejaz, H., Scott, J. B., Wang, N., Gujaran, S., Pickard, D., Wilksch, J. J., Cao, H., Haq, I. U., Dougan, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38943-7 · Cited by 72
Can We Really Use ß-Lactam/ß-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ß-Lactamase–Producing Bacteria?
Pérez, F., & Bonomo, R. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir793 · Cited by 70
Self-citation
Biochemical characterization of New Delhi metallo-β-lactamase variants reveals differences in protein stability
Makena, A., Brem, J., Pfeffer, I., Geffen, R. E. J., Wilkins, S. E., Tarhonskaya, H., Flashman, E., Phee, L. M., Wareham, D. W., & Schofield, C. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku403 · Cited by 69
Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria
Zhang, S., Liao, X., Ding, T., & Ahn, J. (2024) · Antibiotics · doi:10.3390/antibiotics13030260 · Cited by 87
Gold nanoparticles antibacterial activity: Does the surface matter?
Sa'ed, M. M., Ayivi, R. D., Wei, J., & Obare, S. O. (2024) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2024.100804 · Cited by 70
Adaptive expression of phage auxiliary metabolic genes in paddy soils and their contribution toward global carbon sequestration
Zhu, D., Liu, S., Sun, M., Yi, X.-Y., Duan, G., Ye, M., Gillings, M. R., & Zhu, Y. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2419798121 · Cited by 79
Bio-inspired resin acid-derived materials as anti-bacterial resistance agents with unexpected activities
Ganewatta, M. S., Chen, Y. P., Wang, J., Zhou, J., Ebalunode, J. O., Nagarkatti, M., Decho, A. W., & Tang, C. (2014) · Chemical Science · doi:10.1039/c4sc00034j · Cited by 69
Design, Synthesis, and Crystal Structures of 6-Alkylidene-2′-Substituted Penicillanic Acid Sulfones as Potent Inhibitors of Acinetobacter baumannii OXA-24 Carbapenemase
Bou, G., Santillana, E., Sheri, A., Beceiro, A., Sampson, J. M., Kalp, M., Bethel, C. R., Distler, A. M., Drawz, S. M., Pagadala, S. R. R., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104092z · Cited by 68
Self-citation
Detection of OXA-1 β-Lactamase Gene of Klebsiella pneumoniae from Blood Stream Infections (BSI) by Conventional PCR and In-Silico Analysis to Understand the Mechanism of OXA Mediated Resistance
Sugumar, M., Kumar, K. M., Manoharan, A., Anbarasu, A., & Ramaiah, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091800 · Cited by 67
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
Kokai‐Kun, J. F., Roberts, T., Coughlin, O., Sicard, É., Rufiange, M., Fedorak, R. N., Carter, C., Adams, M. H., Longstreth, J. A., Whalen, H., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02197-16 · Cited by 73
Synergistic Role of Plant Extracts and Essential Oils against Multidrug Resistance and Gram-Negative Bacterial Strains Producing Extended-Spectrum β-Lactamases
Alam, M., Bano, N., Ahmad, T., Sharangi, A. B., Upadhyay, T. K., Alraey, Y., Alabdallah, N. M., Rauf, M. A., & Saeed, M. (2022) · Antibiotics · doi:10.3390/antibiotics11070855 · Cited by 86
Diaryl‐Substituted Azolylthioacetamides: Inhibitor Discovery of New Delhi Metallo‐β‐Lactamase‐1 (NDM‐1)
Zhang, Y., Yang, K., Zhou, Y., LaCuran, A. E., Oelschlaeger, P., & Crowder, M. W. (2014) · ChemMedChem · doi:10.1002/cmdc.201402249 · Cited by 67
Transition-Metal-Free Amine Oxidation: A Chemoselective Strategy for the Late-Stage Formation of Lactams
Griffiths, R. J., Burley, G. A., & Talbot, E. P. A. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b00021 · Cited by 67
The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group
Rosa, M. D., Verdino, A., Soriente, A., & Marabotti, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020617 · Cited by 74
Assessment of catalytic, antimicrobial and molecular docking analysis of starch-grafted polyacrylic acid doped BaO nanostructures
Ikram, M., Haider, A., Imran, M., Haider, J., Naz, S., Ul‐Hamid, A., Shahzadi, A., Ghazanfar, K., Nabgan, W., Moeen, S., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123190 · Cited by 66
Metal organic frameworks for drug delivery and environmental remediation: A molecular docking approach
Rodrigues, M. O., de Paula, M. V., Wanderley, K. A., Alves, I. B. V., Alves, S., & Soares, T. A. (2012) · International Journal of Quantum Chemistry · doi:10.1002/qua.24211 · Cited by 65
Ceftolozane–tazobactam: A new-generation cephalosporin
Cluck, D. B., Lewis, P. O., Stayer, B., Spivey, J. M., & Moorman, J. P. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150049 · Cited by 66
Triazolylthioacetamide: A Valid Scaffold for the Development of New Delhi Metallo-β-Lactmase-1 (NDM-1) Inhibitors
Zhai, L., Zhang, Y., Kang, J. S., Oelschlaeger, P., Xiao, L., Nie, S.-S., & Yang, K. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00495 · Cited by 66
Plant-Derived Antimicrobials: Insights into Mitigation of Antimicrobial Resistance
Yang, S.-K., Low, L.-Y., Yap, P. S. X., Yusoff, K., Mai, C., Lai, K., & Lim, S. E. (2018) · Records of Natural Products · doi:10.25135/rnp.41.17.09.058 · Cited by 67
1,2,4‐Triazole‐3‐thione Compounds as Inhibitors of Dizinc Metallo‐β‐lactamases
Sevaille, L., Gavara, L., Bebrone, C., Luca, F. D., Nauton, L., Achard, M. E. S., Mercuri, P. S., Tanfoni, S., Borgianni, L., Guyon, C., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700186 · Cited by 65
Providing β-Lactams a Helping Hand: Targeting the Ampc β-Lactamase Induction Pathway
Mark, B. L., Vocadlo, D. J., & Oliver, A. (2011) · Future Microbiology · doi:10.2217/fmb.11.128 · Cited by 65
Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity
Miyamoto, Y., Kalisiak, J., Korthals, K. A., Lauwaet, T., Cheung, D. Y., Lozano, R., Cobo, E. R., Upcroft, P., Upcroft, J., Berg, D. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302664110 · Cited by 65
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening
Christopeit, T., Carlsen, T. J. O., Helland, R., & Leiros, H. S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01289 · Cited by 65
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
Shapiro, A. B., Gao, N., Jahić, H., Carter, N., Chen, A., & Miller, A. A. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00113 · Cited by 65
Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review
Tuon, F. F., Rocha, J. L. L., & Formigoni-Pinto, M. R. (2017) · Infection · doi:10.1007/s15010-017-1096-y · Cited by 66
Magnolol restores the activity of meropenem against NDM-1-producing Escherichia coli by inhibiting the activity of metallo-beta-lactamase
Liu, S., Zhou, Y., Niu, X., Wang, T., Li, J., Liu, Z., Wang, J., Tang, S., Wang, Y., & Deng, X. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0029-6 · Cited by 65
Bimetallic Ag/Cu incorporated into chemically exfoliated MoS 2 nanosheets to enhance its antibacterial potential: in silico molecular docking studies
Ikram, M., Abbasi, S., Haider, A., Naz, S., Ul‐Hamid, A., Imran, M., Haider, J., & Ghaffar, A. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab8087 · Cited by 65
Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance
Pieren, M., & Tigges, M. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.005 · Cited by 64
NOTA: a potent metallo-β-lactamase inhibitor
Somboro, A. M., Tiwari, D., Bester, L. A., Parboosing, R., Chonco, L., Kruger, H. G., Arvidsson, P. I., Govender, T., Naicker, T., & Essack, S. Y. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku538 · Cited by 64
Antibiotic research in the age of omics: from expression profiles to interspecies communication
Wecke, T., & Mascher, T. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr373 · Cited by 62
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili, A., Izanloo, A., & Rastegar, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2184346 · Cited by 67
Antibiotics: mode of action and mechanisms of resistance
Kaufman, G. (2011) · Nursing Standard · doi:10.7748/ns.25.42.49.s52 · Cited by 66
A Covalent Reporter of β‐Lactamase Activity for Fluorescent Imaging and Rapid Screening of Antibiotic‐Resistant Bacteria
Shao, Q., Zheng, Y. Q., Dong, X., Tang, K., Yan, X., & Xing, B. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201301654 · Cited by 64
Antibiofilm and Anti-��-Lactamase Activities of Burdock Root Extract and Chlorogenic Acid against Klebsiella pneumoniae
Rajasekharan, S. K., Ramesh, S., Satish, A. S., & Lee, J. (2017) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1609.09043 · Cited by 63
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
Qadri, H., Shah, A. H., & Mir, M. A. (2020) · Current Drug Targets · doi:10.2174/1389450121666201228123212 · Cited by 64

Authors: Drawz, S. M., & Bonomo, R. A.
Affiliations: Departments of Pathology
United States Department of Veterans Affairs (US)
Corresponding author: Bonomo, Robert A.
ORCID: Bonomo, Robert A.
Venue: Clinical Microbiology Reviews
Publisher: American Society for Microbiology
Published: 2010-01
Volume: 23
Issue: 1
Pages: 160-201
ISSN: 0893-8512 (ISSN-L)
1098-6618
DOI: 10.1128/cmr.00037-09
PMC: PMC2806661
OpenAlex: W1895007034
Cited by: 1,709
References: 464
Citations by year: 2026: 83 · 2025: 100 · 2024: 87 · 2023: 86 · 2022: 106 · 2021: 126 · 2020: 151 · 2019: 130 · 2018: 131 · 2017: 119 · 2016: 120 · 2015: 108 · 2014: 93 · 2013: 88 · 2012: 81
FWCI: 4.26
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Clinical Microbiology Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Public Health Service (1R01A1063517-01)
National Institute of General Medical Sciences (T32GM007250, T32GM07250)
Topics: Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Physical Sciences › Chemistry › Organic Chemistry › Synthesis of β-Lactam Compounds
Keywords: beta-lactamase inhibitors, beta-lactamase, beta-lactam resistance, clavulanic acid, sulbactam, tazobactam, mechanism-based inactivators, carbapenemase inhibitors, extended-spectrum cephalosporin resistance, Enterobacteriaceae, penicillin-resistant staphylococci
MeSH terms: Bacteria, Bacterial Infections, Bacterial Proteins, beta-Lactamases, Enzyme Inhibitors, Humans, beta-Lactam Resistance, beta-Lactamase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Three Decades of β-Lactamase Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks